Login to Your Account



La Jolla reshuffles drug deck, adds rare genetic disease play

By Marie Powers
News Editor

Friday, May 8, 2015
A week after reporting first quarter financials and continuing to tout GCS−100 as a first-in-class galectin-3 inhibitor to treat chronic kidney disease (CKD), La Jolla Pharmaceutical Co. is ditching the candidate, along with follow-on LJPC−1010, its second-generation galectin-3 inhibitor.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription